Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Son of Sevenless 1: The pacemaker of KRAS.

Current opinion in chemical biology - 1 Jun 2021

Kessler Dirk, Gerlach Daniel, Kraut Norbert, McConnell Darryl B

Abstract excerpt

Son of Sevenless (SOS) is a guanine nucleotide exchange factor that activates the important cell signaling switch KRAS. SOS acts as a pacemaker for KRAS, the beating heart of cancer, by catalyzing the "beating" from the KRAS(off) to the KRAS(on) conformation. Activating mutations in SOS1 are common in Noonan syndrome and oncogenic alterations in KRAS drive 1 in seven human cancers. Promising clinical efficacy has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Mutant Proteins
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to SOS1 Protein

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 33848766
DOI: 10.1016/j.cbpa.2021.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Son of Sevenless 1: The pacemaker of KRAS.PMID 33848766Read ↗

Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.Semantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.Semantic proximity Read ↗

Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Semantic proximity Read ↗

Discovery of a potent and orally available SOS1 inhibitor with antitumor efficacy in KRAS-mutant colorectal cancers.Semantic proximity Read ↗

Computational insights on the molecular interplay between KRas (G12D mutation) and SOS1 modulated by the inhibitor BI-3406.Semantic proximity Read ↗

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.